

Silvia Amoretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/486704/publications.pdf>

Version: 2024-02-01

64
papers

1,742
citations

394421

19
h-index

302126

39
g-index

67
all docs

67
docs citations

67
times ranked

2243
citing authors

#	ARTICLE	IF	CITATIONS
1	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	7.4	528
2	Resilience and mental health during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021, 283, 156-164.	4.1	98
3	The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1638-1648.	0.7	89
4	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. <i>Frontiers in Psychiatry</i> , 2018, 9, 641.	2.6	79
5	Effects of the COVID-19 pandemic and lockdown in Spain: comparison between community controls and patients with a psychiatric disorder. Preliminary results from the BRIS-MHC STUDY. <i>Journal of Affective Disorders</i> , 2021, 281, 13-23.	4.1	70
6	Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 441-455.	4.5	66
7	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017, 189, 84-90.	2.0	49
8	Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2019, 45, 846-858.	4.3	41
9	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. <i>Psychological Medicine</i> , 2018, 48, 2247-2256.	4.5	40
10	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e182.	3.9	36
11	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	4.3	32
12	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 699-711.	3.2	31
13	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. <i>Journal of Clinical Medicine</i> , 2019, 8, 586.	2.4	31
14	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>Psychological Medicine</i> , 2020, 50, 2702-2710.	4.5	31
15	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
16	Persistent Negative Symptoms in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1414-1422.	2.2	28
17	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. <i>European Psychiatry</i> , 2020, 63, e71.	0.2	27
18	Affective versus non-affective first episode psychoses: A longitudinal study. <i>Journal of Affective Disorders</i> , 2018, 238, 297-304.	4.1	26

#	ARTICLE	IF	CITATIONS
19	Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 529-541.	6.1	23
20	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	7.9	23
21	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. <i>European Neuropsychopharmacology</i> , 2021, 47, 98-111.	0.7	21
22	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. <i>European Neuropsychopharmacology</i> , 2021, 47, 112-129.	0.7	20
23	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.2	18
24	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. <i>Psychological Medicine</i> , 2022, 52, 526-537.	4.5	17
25	Trajectories of suicidal ideation after first-episode psychosis: a growth mixture modeling approach. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 418-433.	4.5	17
26	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 786-794.	0.7	16
27	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
28	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	4.3	14
29	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	4.5	14
30	Cognitive reserve in mental disorders. <i>European Neuropsychopharmacology</i> , 2021, 49, 113-115.	0.7	14
31	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 73.	2.4	14
32	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, 14, 164-176.	1.8	13
33	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021, 11, 423.	4.8	12
34	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. <i>European Neuropsychopharmacology</i> , 2021, 49, 54-68.	0.7	12
35	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020, 46, 846-856.	4.3	10
36	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	4.5	10

#	ARTICLE	IF	CITATIONS
37	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2474.	2.4	10
38	Cognitive clusters in first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 237, 31-39.	2.0	10
39	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	4.8	10
40	Spatial Suppression and Sensitivity for Motion in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	9
41	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2020, 223, 345-352.	2.0	8
42	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. <i>Psychopharmacology</i> , 2021, 238, 665-676.	3.1	8
43	Food craving and consumption evolution in patients starting treatment with clozapine. <i>Psychopharmacology</i> , 2019, 236, 3317-3327.	3.1	7
44	Self-reported neurocognitive symptoms during COVID-19 lockdown and its associated factors in a sample of psychiatric patients. Results from the BRIS-MHC study. <i>European Neuropsychopharmacology</i> , 2021, 53, 7-18.	0.7	7
45	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	2.0	6
46	Sex differences in neurocognitive and psychosocial functioning in bipolar disorder. <i>Journal of Affective Disorders</i> , 2022, 296, 208-215.	4.1	6
47	Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 75-80.	1.4	6
48	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 236, 19-28.	2.0	5
49	The role of genetics in cognitive remediation in schizophrenia: A systematic review. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100146.	1.3	4
50	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. <i>Psychological Medicine</i> , 2021, 51, 2044-2053.	4.5	4
51	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. <i>Journal of Affective Disorders</i> , 2022, 302, 83-93.	4.1	4
52	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 36-50.	4.5	4
53	Shaped before birth: Obstetric complications identify a more severe clinical phenotype among patients presenting a first affective or non-affective episode of psychosis. <i>Journal of Psychiatric Research</i> , 2022, 151, 461-468.	3.1	4
54	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021, 14, 164-176.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De Psiquiatr�a Y Salud Mental, 2021, , .	1.8	3
56	Cortical thinning over two years after first-episode psychosis depends on age of onset. NPJ Schizophrenia, 2022, 8, 20.	3.6	3
57	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. Psychological Medicine, 2023, 53, 4634-4647.	4.5	3
58	Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. Psychological Medicine, 2023, 53, 3065-3076.	4.5	2
59	Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance. Revista De Psiquiatr�a Y Salud Mental, 2022, , .	1.8	1
60	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S318-S318.	4.3	0
61	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S157-S158.	4.3	0
62	M123. EPISODIC VERBAL MEMORY DEFICIT IN SCHIZOPHRENIA: A MARKER OF PROGRESSION OF DISEASE OR DIFFERENT NEURODEVELOPMENTAL PATHWAYS FROM THE ONSET?. Schizophrenia Bulletin, 2020, 46, S182-S182.	4.3	0
63	M176. INTESTINAL PERMEABILITY AND LOW-GRADE CHRONIC INFLAMMATION IN SCHIZOPHRENIA: DO THEY INFLUENCE COGNITION AND COGNITIVE RESERVE?. Schizophrenia Bulletin, 2020, 46, S203-S204.	4.3	0
64	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De Psiquiatr�a Y Salud Mental (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		